Mitsubishi UFJ Trust & Banking
NBIX icon

Mitsubishi UFJ Trust & Banking’s Neurocrine Biosciences NBIX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Buy
104,854
+32,946
+46% +$4.89M 0.04% 377
2026
Q1 		$9.47M Sell
71,908
-7,987
-10% -$1.06M 0.02% 506
2025
Q4 		$11.3M Buy
79,895
+847
+1% +$123K 0.03% 494
2025
Q3 		$11.1M Sell
79,048
-20,978
-21% -$2.84M 0.02% 538
2025
Q2 		$12.6M Sell
100,026
-14,782
-13% -$1.7M 0.03% 491
2025
Q1 		$12.7M Sell
114,808
-6,334
-5% -$802K 0.03% 479
2024
Q4 		$16.5M Sell
121,142
-4,578
-4% -$566K 0.04% 428
2024
Q3 		$14.5M Buy
125,720
+811
+0.6% +$111K 0.03% 494
2024
Q2 		$17.2M Buy
124,909
+12,191
+11% +$1.67M 0.04% 416
2024
Q1 		$15.5M Sell
112,718
-4,509
-4% -$616K 0.04% 464
2023
Q4 		$15.4M Buy
117,227
+18,687
+19% +$2.15M 0.04% 453
2023
Q3 		$11.1M Sell
98,540
-481
-0.5% -$50.6K 0.03% 510
2023
Q2 		$9.34M Buy
99,021
+9,208
+10% +$900K 0.02% 563
2023
Q1 		$9.09M Buy
89,813
+9,330
+12% +$971K 0.02% 569
2022
Q4 		$9.61M Buy
80,483
+2,039
+3% +$239K 0.03% 554
2022
Q3 		$8.33M Sell
78,444
-29,938
-28% -$3.04M 0.02% 562
2022
Q2 		$10.6M Buy
108,382
+24,344
+29% +$2.25M 0.03% 532
2022
Q1 		$7.88M Sell
84,038
-12,335
-13% -$1.05M 0.02% 624
2021
Q4 		$8.21M Buy
96,373
+34,348
+55% +$3.16M 0.02% 637
2021
Q3 		$5.95M Sell
62,025
-1,421
-2% -$134K 0.01% 716
2021
Q2 		$6.18M Buy
63,446
+6,153
+11% +$590K 0.01% 724
2021
Q1 		$5.57M Sell
57,293
-12,631
-18% -$1.32M 0.01% 713
2020
Q4 		$6.7M Sell
69,924
-1,862
-3% -$180K 0.01% 700
2020
Q3 		$6.9M Buy
71,786
+2,381
+3% +$275K 0.02% 658
2020
Q2 		$8.47M Sell
69,405
-222
-0.3% -$24.5K 0.02% 591
2020
Q1 		$6.03M Buy
69,627
+5,292
+8% +$518K 0.02% 617
2019
Q4 		$6.92M Buy
+64,335
New +$6.74M 0.02% 684

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's NBIX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking increased its Neurocrine Biosciences (NBIX) stake by 46% in Q2 2026, buying an estimated $4.89M and bringing the position to 104,854 shares worth $17.7M. The position accounts for 0.04% of the portfolio, ranked #377.

Mitsubishi UFJ Trust & Banking first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Mitsubishi UFJ Trust & Banking held 104,854 shares of Neurocrine Biosciences worth $17.7M as of Q2 2026.
  • Mitsubishi UFJ Trust & Banking bought 32,946 Neurocrine Biosciences shares in Q2 2026, an estimated $4.89M.
  • Neurocrine Biosciences made up 0.04% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #377 holding.
  • Mitsubishi UFJ Trust & Banking first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.